Biogen
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Biogen and other ETFs, options, and stocks.About BIIB
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.
BIIB Key Statistics
Stock Snapshot
As of today, Biogen(BIIB) shares are valued at $194.24. The company's market cap stands at 28.67B, with a P/E ratio of 21.37.
As of 2026-06-10, Biogen(BIIB) stock has fluctuated between $194.10 and $201.94. The current price stands at $194.24, placing the stock +0.1% above today's low and -3.8% off the high.
The Biogen(BIIB)'s current trading volume is 1.07M, compared to an average daily volume of 988.24K.
During the past year, Biogen(BIIB) stock moved between $121.05 at its lowest and $205.97 at its peak.
During the past year, Biogen(BIIB) stock moved between $121.05 at its lowest and $205.97 at its peak.
BIIB News
After not buying or selling any stocks in 2025, a congresswoman who made over $2.4 million in trades in 2024 is buying stocks once again in 2026. Here's a look...
Biogen ( (BIIB) ) has issued an announcement. On June 9, 2026, Biogen Inc. held its 2026 Annual Meeting of Stockholders, where shareholders elected ten directo...
...
Analyst ratings
58%
of 38 ratingsMore BIIB News
While Biogen Inc.'s (NASDAQ:BIIB) base business is declining, it is entering a period of pipeline optionality, with eight Phase III readouts through 2029, accor...
Needham upgraded Biogen (BIIB) to Buy from Hold with a $255 price target Biogen is entering a phase of eight Phase 3 readouts through 2029 amid an improved outl...
Needham upgraded Biogen (BIIB) to Buy from Hold with a $255 price target Published first on TheFly – the ultimate source for real-time, market-moving breaking...
Biogen Inc. (BIIB) announced an update on their ongoing clinical study. Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings...
UCB and Biogen (BIIB) announced data, comprising two posters and three abstracts, at the European Alliance of Associations for Rheumatology, or EULAR, 2026 Cong...
In May 2026, Biogen’s partner UCB reported positive Phase 3 PHOENYCS GO results for dapirolizumab pegol in moderate-to-severe active systemic lupus erythematosu...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.